PharmaGap Inc. Provides Guidance on Timing of Testing at National Cancer Institute

Ottawa, Ontario/May 7, 2009 – PharmaGap Inc. (TSX-V: GAP) (“PharmaGap” or “the Company”) today announced that the National Cancer Institute (“NCI”) has confirmed receipt of PharmaGap’s drug product PhG-alpha-1 at its drug depository in Rockville, MD, in advance of testing in the NCI’s tumour cell panel consisting of 60 human cancer cell lines. The NCI has advised the Company that the results of the initial single dose test could normally be expected in a minimum of six to ten weeks.

About The National Cancer Institute

The National Cancer Institute is an institute of the National Institutes of Health, the primary U.S. Federal Agency for conducting and supporting medical research. The NCI’s mandate is to conduct and foster cancer research in the United States, and is located in Bethesda, Maryland. For more information please visit www.cancer.gov.

About PharmaGap Inc.

PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signalling pathways controlled by Protein Kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhG-alpha-1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information please visit www.pharmagap.com.

Note: The TSX-Venture Exchange does not accept responsibility for the adequacy or accuracy of this release. No Securities Commission or other regulatory authority having jurisdiction over PharmaGap has approved or disapproved of the information contained herein. This release contains forward looking statements that may not occur or may change materially.